US OptionsDetailed Quotes

NAUT241220P12500

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 26 09:30 ET

0.00High0.00Low

Nautilus Biotechnology Stock Discussion

TechWhiz

Oct 3 21:56

Wulf sold Nautilus stake... good or bad?

I think good as Patrick Fluery hinted the cost associated with Nautilus is much higher than Lake Mariner.
Now they have the money to expand into AI/HPC without having to go into debt again.
Looks like it will be a hyper scaler customer. Normally such big customers are careful and want to make sure they get a good deal. Wulf I'd preparing all the buildings n equipment, etc.
Hopefully wulf will transform into a big data centre play. Then the price will 10,...

Moomoo Recap US

Oct 20, 2021 08:58

Columns 6 Innovative Companies in Jeff Bezos's Portfolio

$Remitly Global (RELY.US)$ $Domo Inc (DOMO.US)$ $Air Transport Services (ATSG.US)$ $Vital Farms (VITL.US)$ $Nautilus Biotechnology (NAUT.US)$

Expand

101610778

Sep 7, 2021 08:53

Just bought a bit of shares

$Nautilus Biotechnology (NAUT.US)$

OCEAN88888888

Jul 22, 2021 07:53

$Inhibikase Therapeutics (IKT.US)$
$Inhibikase Therapeutics (IKT.US)$
$Inhibikase Therapeutics (IKT.US)$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$CohBar (CWBR.US)$
$CohBar (CWBR.US)$
..........................................
$Fulcrum Therapeutics (FULC.US)$

JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12

No comment yet